Back to search results

Epidemiology and Biomarker Study in Alzheimer's Disease (AACU)

This study, called AACU, is looking at how Alzheimer's disease develops over time. It involves a plasma test called P-tau217, which measures a specific protein in your blood. Researchers want to see if the levels of this protein are linked to changes in your thinking and memory. You might be able to join if you are between 55 and 75 years old and currently have no memory concerns. The main goal is to see how long it takes for thinking abilities to worsen in people with different P-tau217 levels. The study is currently unclear about its recruitment status and plans to enroll about 3400 participants.

Study design
This is an interventional study that does not involve a drug. It plans to enroll about 3400 participants.
What's involved
You would have an annual P-tau217 blood test. Your participation in the study will last approximately 7 years.
Compensation
Not stated in the trial record.
Follow-up
Your cognitive worsening will be measured from the start of the study up to 7 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07142954

Epidemiology and Biomarker Study in Alzheimer's Disease

Recruiting
PHASE3Ages 55–75Interventional
Eli Lilly and Company
~3,400 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:P-tau217 Test

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to Cognitive Worsening Within Cohorts as Measured by Cognitive Composite or Any of the Individual Composite Components
Measured over Baseline up to 7 years

Conditions

Alzheimer Disease

Explore related trials

Alzheimer's DiseasePreclinical Alzheimer's Disease

Where it's being run

4 sites across 2 states
Japan3
Texas1

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
1-317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

The participant must self-report unimpaired cognition.
The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening.

Exclusion

Have seen a doctor about memory concerns.
Have a history or diagnosis of cognitive impairment, or significant other neurodegenerative disease that can affect cognition.
Are currently enrolled or have previously participated in any Alzheimer's Disease (AD)-related study involving an investigational drug intervention.
Are currently using or have previously used prescription medications for treatment of mild cognitive impairment (MCI) or dementia such as amyloid targeting therapy (that is, lecanemab, donanemab, aducanumab), cholinesterase inhibitors (for example, benzgalantamine, donepezil, galantamine, rivastigmine), and memantine.

What this trial measures

  • Time to Cognitive Worsening Within Cohorts as Measured by Cognitive Composite or Any of the Individual Composite ComponentsBaseline up to 7 years

    Cognitive composite may consist of International Daily Symbol Substitution Test-Medicines (iDSSTm ), International Shopping List Test (ISLT), Continuous Paired Associate Learning Test (CPAL). Time to cognitive worsening is defined as a change in cognitive composite score or any of the individual composite components, from baseline at 2 consecutive visits.